Street Calls of the Week
NORTH CHARLESTON, S.C. - Ingevity Corporation (NYSE:NGVT), a specialty chemicals manufacturer with a market capitalization of $2.1 billion and trading near its 52-week high of $58.73, has entered into a definitive agreement to sell its North Charleston crude tall oil (CTO) refinery assets and most of its Performance Chemicals Industrial Specialties product line to Mainstream Pine Products, LLC for approximately $110 million in cash, with potential additional contingent payments of up to $19 million. According to InvestingPro analysis, the company has demonstrated strong market performance with a 54.79% return over the past year.
The transaction, expected to close by early 2026, is subject to customary closing conditions. The assets being divested are expected to generate approximately $130 million in revenue for 2025 with EBITDA margins in the low-to-mid single digits, according to a company press release. This represents about 10% of Ingevity’s last twelve months revenue of $1.32 billion. InvestingPro data shows the company maintains a "GOOD" overall financial health score, with particularly strong momentum metrics.
As part of the deal, Mainstream will supply certain refinery products to support Ingevity’s Road Technologies product line. Ingevity will also provide toll-manufacturing services for certain Industrial Specialties products and deliver operating services to Mainstream at the North Charleston CTO refinery after closing.
"This transaction marks a significant milestone for Ingevity, reducing portfolio volatility, strengthening our margin and cash flow profile and enhancing future strategic optionality," said Dave Li, Ingevity’s president and CEO.
The companies noted that the transaction will not impact production of Ingevity’s Road Technologies product line or certain lignin-based dispersants manufactured at the North Charleston plant.
Beginning with third quarter reporting, the combined assets being sold will be reported as discontinued operations. Ingevity affirmed its previously provided full-year 2025 guidance of sales between $1.25 billion and $1.40 billion and adjusted EBITDA between $390 million and $415 million, not accounting for the reclassification. The company’s current EBITDA stands at $392.8 million, with InvestingPro analysis indicating strong cash flow generation potential. Investors seeking deeper insights can access comprehensive analysis and 12 additional ProTips through InvestingPro’s detailed research reports.
Ingevity plans to use the transaction proceeds to accelerate deleveraging and provide additional capital allocation flexibility. The company stated it continues to advance its portfolio review with a focus on sustainable growth and profitability.
Headquartered in North Charleston, South Carolina, Ingevity (NYSE:NGVT) develops and manufactures products for applications including adhesives, agrochemicals, asphalt paving, and automotive components. Based on InvestingPro’s Fair Value analysis, the stock currently appears slightly overvalued, though analysts have recently revised earnings expectations upward for the upcoming period.
In other recent news, Ingevity Corporation reported its second-quarter earnings for 2025, revealing a significant earnings per share (EPS) beat. The actual EPS of $1.39 surpassed the forecasted $1.16, marking a 19.83% surprise. Despite this positive earnings performance, the company’s revenue fell short of expectations, totaling $365 million compared to the anticipated $378.7 million. Additionally, BMO Capital raised its price target for Ingevity to $62 from $56, maintaining an Outperform rating. The firm noted an inflection point in Ingevity’s earnings and free cash flow, indicating potential for further growth. These developments highlight a positive outlook from analysts despite the revenue miss. The market reaction was notably positive, driven by strong operational performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.